BioCryst director granted 1,288 shares

A BioCryst director received stock in lieu of a cash board retainer, modestly increasing direct holdings.

Rhea-AI Filing Summary

BIOCRYST PHARMACEUTICALS INC (symbol: BCRX) is the issuer of record for a Form 4 filing submitted to the SEC. Milne Jill C. reported acquisition or exercise transactions in this Form 4 filing.

BIOCRYST PHARMACEUTICALS INC (BCRX) reported that director Jill C. Milne received a grant of 1,288 shares of Common Stock on August 31, 2026, as a board compensation award. The shares were issued in lieu of a $12,500 quarterly cash Board Member retainer, bringing her directly held stake to 33,226 shares. No Rule 10b5-1 trading plan is reported for this transaction.

Insider Trade Summary

Grant/Award: 1,288 shares

Grant/Award 1 txn

Insider Milne Jill C.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock F1	1,288	$9.70	$12K

Holdings After Transaction: Common Stock — 33,226 shares (Direct)

Footnotes (1)

1. F1. Shares of Common Stock issued to the reporting person in lieu of 100% of the quarterly cash Board Member retainer of $12,500.

Key Figures

Shares awarded: 1,288 shares Award reference price: $9.70 per share Quarterly Board Member retainer: $12,500 +1 more

4 metrics

Shares awarded 1,288 shares Grant of Common Stock on August 31, 2026 to director Jill C. Milne

Award reference price $9.70 per share Value used for the stock issued in lieu of cash retainer

Quarterly Board Member retainer $12,500 Cash retainer fully paid in stock instead of cash

Shares owned after transaction 33,226 shares Director’s directly held Common Stock following the award

Key Terms

grant, award, or other acquisition, quarterly cash Board Member retainer, Common Stock, direct ownership

4 terms

grant, award, or other acquisition financial

"Transaction reported as a grant, award, or other acquisition of shares"

quarterly cash Board Member retainer financial

"Shares issued in lieu of 100% of the quarterly cash Board Member retainer"

Common Stock financial

"Shares of Common Stock issued to the reporting person in lieu of cash"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

direct ownership financial

"Total of 33,226 shares reported as directly owned after the transaction"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did BCRX director Jill C. Milne report?

She reported an acquisition of 1,288 shares of Common Stock on August 31, 2026, as a grant or award, rather than an open-market trade. The shares were issued as compensation for her board service.

How was the BCRX board retainer paid in this Form 4 event?

The director’s $12,500 quarterly cash Board Member retainer was paid entirely in stock, with 1,288 shares of Common Stock issued in lieu of cash, at a reference amount of $9.70 per share as disclosed.

What are Jill C. Milne’s BCRX holdings after this transaction?

After the August 31, 2026 award, Jill C. Milne directly holds 33,226 shares of BioCryst Pharmaceuticals Common Stock, according to the filing.

Was the reported BCRX insider transaction under a Rule 10b5-1 plan?

No. The filing indicates no Rule 10b5-1 trading plan for this transaction; it is reported simply as a grant or award of shares for board compensation.

Did the BCRX director buy or sell shares on the open market?

No open-market purchase or sale is reported. The Form 4 shows a grant/award acquisition of 1,288 shares as compensation, not a market trade.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/02/2026 - 04:13 PM EDT Accepted by SEC EDGAR 09/02/2026 - 04:13 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Milne Jill C.

(Last) (First) (Middle)

4505 EMPEROR BLVD

SUITE 200

(Street)

DURHAM NORTH CAROLINA 27703

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BIOCRYST PHARMACEUTICALS INC [ BCRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/31/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/31/2026		A		1,288(1)	A	$9.7	33,226	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares of Common Stock issued to the reporting person in lieu of 100% of the quarterly cash Board Member retainer of $12,500.

	/s/ Alane P. Barnes, by power of attorney	09/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)